- Home
- CDRE vs DAWN Comparison
CDRE vs DAWN Comparison
Compare CDRE & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDRE
- DAWN
- Stock Information
- Founded
- CDRE 2012
- DAWN 2018
- Country
- CDRE United States
- DAWN United States
- Employees
- CDRE N/A
- DAWN N/A
- Industry
- CDRE Industrial Specialties
- DAWN Biotechnology: Pharmaceutical Preparations
- Sector
- CDRE Health Care
- DAWN Health Care
- Exchange
- CDRE Nasdaq
- DAWN Nasdaq
- Market Cap
- CDRE 1.3B
- DAWN 1.3B
- IPO Year
- CDRE 2021
- DAWN 2021
- Fundamental
- Price
- CDRE $38.17
- DAWN $12.54
- Analyst Decision
- CDRE Buy
- DAWN Strong Buy
- Analyst Count
- CDRE 5
- DAWN 7
- Target Price
- CDRE $39.75
- DAWN $36.33
- AVG Volume (30 Days)
- CDRE 322.5K
- DAWN 1.2M
- Earning Date
- CDRE 03-04-2025
- DAWN 02-24-2025
- Dividend Yield
- CDRE 0.92%
- DAWN N/A
- EPS Growth
- CDRE N/A
- DAWN N/A
- EPS
- CDRE 0.83
- DAWN N/A
- Revenue
- CDRE $516,159,999.00
- DAWN $101,953,000.00
- Revenue This Year
- CDRE $19.08
- DAWN N/A
- Revenue Next Year
- CDRE $8.30
- DAWN $35.22
- P/E Ratio
- CDRE $46.12
- DAWN N/A
- Revenue Growth
- CDRE 7.18
- DAWN N/A
- 52 Week Low
- CDRE $29.19
- DAWN $11.13
- 52 Week High
- CDRE $40.28
- DAWN $18.07
- Technical
- Relative Strength Index (RSI)
- CDRE 72.96
- DAWN 49.68
- Support Level
- CDRE $31.56
- DAWN $11.13
- Resistance Level
- CDRE $32.72
- DAWN $13.30
- Average True Range (ATR)
- CDRE 1.08
- DAWN 0.51
- MACD
- CDRE 0.60
- DAWN 0.05
- Stochastic Oscillator
- CDRE 96.31
- DAWN 64.98
About CDRE Cadre Holdings Inc.
Cadre Holdings Inc is engaged in the design and manufacture of a diversified product portfolio of critical safety and survivability equipment to protect first responders, federal agencies, outdoor recreation, and personal protection markets. The Company's equipment provides critical protection to allow its users to safely and securely perform their duties and protect those around them in hazardous or life-threatening situations. Its operations are comprised of two reportable segments: Products and Distribution.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.